As of the latest Form 4 filed Jun 15, 2026.
What Century Therapeutics Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 23 most recent filings for IPSC.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-15 | 2026-06-12 | Russotti Gregory See Remarks | SSale | −2.58K | $2.23 | $5.77K | No | Form 4 ↗ |
| 2026-06-15 | 2026-06-12 | Carr Douglas SVP Finance & Operations | SSale | −1.65K | $2.23 | $3.69K | No | Form 4 ↗ |
| 2026-06-15 | 2026-06-11 | Cowan Chad Chief Scientific Officer | FTax | −358.00 | $2.24 | $801.92 | No | Form 4 ↗ |
| 2026-06-15 | 2026-06-11 | Pfeiffenberger Brent President and CEO | FTax | −13.8K | $2.24 | $31.0K | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-08 | Russotti Gregory See Remarks | SSale | −524.00 | $2.11 | $1.11K | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-08 | Carr Douglas SVP Finance & Operations | SSale | −249.00 | $2.11 | $525.64 | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | Pfeiffenberger Brent President and CEO | FTax | −463.00 | $2.13 | $986.19 | No | Form 4 ↗ |
| 2026-05-19 | 2026-05-15 | Pfeiffenberger Brent President and CEO | FTax | −31.2K | $2.34 | $72.9K | No | Form 4 ↗ |
| 2026-05-06 | 2026-05-04 | Carr Douglas SVP Finance & Operations | SSale | −264.00 | $2.34 | $618.02 | No | Form 4 ↗ |
| 2026-04-03 | 2026-04-01 | Cowan Chad Chief Scientific Officer | FTax | −1.36K | $2.19 | $2.99K | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-12 | Russotti Gregory See Remarks | SSale | −10.1K | $2.55 | $25.7K | No | Form 4 ↗ |
| 2026-03-16 | 2026-03-12 | Carr Douglas SVP Finance & Operations | SSale | −7.04K | $2.55 | $18.0K | No | Form 4 ↗ |
| 2026-03-13 | 2026-03-11 | Cowan Chad Chief Scientific Officer | FTax | −1.43K | $2.73 | $3.91K | No | Form 4 ↗ |
| 2026-03-13 | 2026-03-11 | Pfeiffenberger Brent President and CEO | FTax | −55.4K | $2.73 | $151K | No | Form 4 ↗ |
| 2026-03-11 | 2026-03-09 | Russotti Gregory See Remarks | SSale | −479.00 | $2.54 | $1.21K | No | Form 4 ↗ |
| 2026-03-11 | 2026-03-09 | Carr Douglas SVP Finance & Operations | SSale | −247.00 | $2.54 | $626.39 | No | Form 4 ↗ |
| 2026-03-10 | 2026-03-06 | Pfeiffenberger Brent President and CEO | FTax | −463.00 | $2.56 | $1.19K | No | Form 4 ↗ |
| 2026-02-18 | 2026-02-13 | Pfeiffenberger Brent President and CEO | FTax | −31.2K | $1.75 | $54.6K | No | Form 4 ↗ |
| 2026-02-05 | 2026-02-03 | Carr Douglas SVP Finance & Operations | SSale | −323.00 | $1.82 | $588.51 | No | Form 4 ↗ |
| 2026-02-04 | 2026-02-02 | Cowan Chad Chief Scientific Officer | AAward | +135K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-04 | 2026-02-02 | Pfeiffenberger Brent President and CEO | AAward | +475K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-04 | 2026-02-02 | Russotti Gregory See Remarks | AAward | +135K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-04 | 2026-02-02 | Carr Douglas SVP Finance & Operations | AAward | +110K | $0.00 | $0.00 | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also IPSC’s full analysis or the market-wide insider trading feed. The tabs above jump to IPSC’s other SEC data.
Source: SEC Form 4 filings for IPSC, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.